Status:
COMPLETED
A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
Lead Sponsor:
Centocor, Inc.
Conditions:
Lymphoma, Non-Hodgkin
Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate of the study of different CNTO 328 doses and schedules and to see if CNTO 328 has any effect on Non-hodgkin's Lymphoma, Multiple Myeloma or Castleman's disease...
Detailed Description
This research study will use a type of drug called anti-IL-6 antibody, also known as CNTO 328. An antibody is a substance in the body that fights infection. CNTO 328 is an investigational drug that ha...
Eligibility Criteria
Inclusion
- Diagnosed with B-cell non-Hodgkin's lymphoma, multiple myeloma, or Castleman's Disease which has progressed on or after standard therapy or for which there is no effective standard therapy, or which is not suitable for standard therapy
- Detectable serum C-Reactive Protein
- At least 4 weeks since prior systemic therapy, radiotherapy, or surgery
- Must meet protocol lab criteria (adequate bone marrow, liver and renal function) to be assessed at patient's first visit to the study center
Exclusion
- Received any investigational drug within 30 days or 5 half-lives of the investigational drug, whichever is longer
- History of receiving murine or human-murine recombination products, such as G250, BE-8, and other monoclonal antibodies. (Note: Prior rituximab treatment is not an exclusion criterion)
- Serious concurrent illness or significant cardiac disease characterized by significant ischemic coronary disease or congestive heart failure
- Known human immunodeficiency virus seropositivity, acquired immunodeficiency syndome, hepatitis C or active hepatitis B infection. For Cohort 7, known human herpesvirus-8 seropositivity
- Presence of a transplanted solid organ (with the exception of a corneal transplant more than 3 months prior to screening) or having received an allogeneic bone marrow transplant or an allogeneic peripheral blood stem cell transplant
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
67 Patients enrolled
Trial Details
Trial ID
NCT00412321
Start Date
May 1 2005
End Date
April 1 2011
Last Update
July 1 2014
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Little Rock, Arkansas, United States
2
Tampa, Florida, United States
3
Atlanta, Georgia, United States
4
Box 302, New York, United States